Branch Retinal Vein Occlusion: Causes, Treatment, and Vision Care
Understanding Branch Retinal Vein Occlusion
The retina is the thin layer of tissue at the back of the eye that detects light and sends visual signals to the brain. Small veins carry blood away from the retina after it has delivered oxygen and nutrients to the nerve cells. In BRVO, one of these branch veins becomes blocked, preventing normal blood flow.
When the vein is blocked, blood and fluid leak out into the surrounding retinal tissue. If this leakage reaches the macula, the central part of the retina responsible for sharp vision, it causes swelling known as macular edema. Macular edema is the most common reason people with BRVO lose vision.
Most cases of BRVO occur at a spot called an arteriovenous crossing. This is a location where a retinal artery and a retinal vein share a common outer tissue layer and physically cross over each other. When the artery wall thickens and loses flexibility, a process linked to atherosclerosis (hardening of the arteries), it compresses the vein beneath it.
The compressed vein develops turbulent blood flow, which promotes the formation of a blood clot, or thrombus. This clot blocks the vein and stops blood from draining properly. The resulting backup of pressure causes fluid to leak into the retina. Over time, poor blood circulation in the affected area can damage or destroy nerve cells, leading to further vision loss.
Retinal vein occlusion comes in two main forms. BRVO affects a branch of the retinal vein, while central retinal vein occlusion (CRVO) affects the main retinal vein where all branches come together. BRVO is four to six times more common than CRVO (ASRS). Because BRVO affects a smaller area of the retina, it may cause less widespread damage, though it can still lead to significant vision problems if the macula is involved.
One of the more serious complications of BRVO is retinal neovascularization. When part of the retina does not receive enough blood, a condition called ischemia, the body may respond by growing abnormal new blood vessels on the retinal surface. These fragile vessels can bleed or cause scar tissue, which may lead to further vision loss or even retinal detachment if not treated.
Who Is Affected and Risk Factors
BRVO most commonly affects people aged 50 and older. Advancing age is a basic risk factor because the blood vessels throughout the body, including those in the eye, become less flexible over time. Pooled research data show an age- and sex-standardized prevalence of about 4.42 per 1,000 people for BRVO (Rogers et al., Ophthalmology, 2010). Some estimates place the overall prevalence between 6 and 12 per 1,000 people (Cleveland Clinic).
Uncontrolled high blood pressure is the single most important systemic risk factor for BRVO. High blood pressure damages and stiffens artery walls, which increases the chance that an artery will compress a nearby vein at a crossing point. Cardiovascular disease, including coronary artery disease and stroke, also raises risk because these conditions share the same underlying process of blood vessel damage.
Diabetes mellitus contributes to BRVO risk by damaging blood vessel walls and promoting abnormal clotting. When diabetes is combined with high blood pressure and high cholesterol, a cluster of conditions known as metabolic syndrome, the risk for retinal vein occlusion increases substantially. People with end-organ damage from diabetes and hypertension face a particularly high risk (PMC review, 2010).
Several additional factors may raise the likelihood of developing BRVO:
- Being overweight or obese, measured by increased body mass index
- High cholesterol or high triglycerides (hyperlipidemia)
- Blood disorders that increase clotting tendency (thrombophilia)
- Conditions that cause thicker-than-normal blood (blood hyperviscosity)
- History of vascular cerebral stroke
Research has identified differences in BRVO risk among racial and ethnic groups. After adjusting for other risk factors, Black individuals had a 43 percent increased risk of developing BRVO compared to non-Hispanic white individuals (adjusted hazard ratio 1.43, Rogers et al., Ophthalmology, 2010). These disparities may reflect higher rates of hypertension and cardiovascular disease in certain populations.
Signs and Symptoms
The hallmark symptom of BRVO is a sudden, painless change in vision. Many people notice blurred or distorted vision in part of their visual field. This can happen all at once or worsen gradually over several hours or days. In some cases, vision loss may be severe and affect all of the vision in the affected eye.
Some people with BRVO notice floaters, which appear as dark spots, lines, or squiggly shapes drifting across the field of vision. These floaters are caused by small clumps of blood leaking from damaged retinal vessels into the vitreous, the gel that fills the inside of the eye. If the blocked vein is not near the macula, BRVO can sometimes go unnoticed because it does not affect central vision.
Any sudden, unexplained change in vision should be taken seriously. If you experience a sudden increase in floaters, flashes of light, a shadow or curtain across part of your vision, or sudden vision loss in one eye, see a retina specialist or go to the emergency room immediately. Early evaluation gives you the best chance of preserving vision.
Diagnosis and Testing
A retina specialist will begin by performing a comprehensive dilated eye exam. Special drops widen the pupil so the specialist can look at the retina in detail. During this exam, the doctor can see signs of vein blockage, including swollen blood vessels, areas of bleeding, and fluid in the retina.
Optical coherence tomography, commonly called OCT, is a non-invasive imaging test that creates detailed cross-sectional pictures of the retina. OCT allows the specialist to measure the thickness of the macula and detect even small amounts of macular edema. This test is used at diagnosis and at follow-up visits to track how well treatment is working.
In fluorescein angiography, a special dye is injected into a vein in the arm. As the dye travels through the blood vessels of the retina, a camera takes rapid photographs. This test shows exactly where blood flow is blocked, where fluid is leaking, and whether any areas of the retina are ischemic (lacking adequate blood supply). It also helps the retina specialist determine whether abnormal new blood vessels have started to grow.
Treatment Options
The primary treatment for macular edema caused by BRVO is intravitreal injection of anti-VEGF medication. Anti-VEGF stands for anti-vascular endothelial growth factor. These drugs block VEGF, a protein that promotes abnormal blood vessel growth and fluid leakage in the retina. By reducing VEGF levels, these injections help decrease swelling in the macula and can improve vision.
Several anti-VEGF medications are used for BRVO. Eylea (aflibercept) is FDA-approved for the treatment of macular edema following retinal vein occlusion. It is typically given every four to eight weeks after an initial loading phase. Avastin (bevacizumab), which is FDA-approved for cancer treatment, is frequently used off-label for macular edema in BRVO, with clinical evidence supporting its effectiveness. Lucentis (ranibizumab) is also FDA-approved for this use, typically given every four weeks. Vabysmo (faricimab), a newer bispecific antibody, has shown results comparable to aflibercept in clinical trials for treating BRVO and CRVO, with the potential for longer intervals between injections of up to four to sixteen weeks.
Because macular edema tends to return after the medication wears off, anti-VEGF injections typically need to be given on a regular schedule. The retina specialist will monitor your response using OCT scans and adjust the treatment interval based on how your eye responds. Some people need injections monthly, while others may eventually extend to longer intervals. Research has shown that patients with BRVO who receive frequent anti-VEGF injections during the first year achieve meaningful vision improvements, and long-term studies indicate that these gains can be maintained with ongoing care (ASRS).
For patients who do not respond well to anti-VEGF therapy, corticosteroid options may be considered. Ozurdex (dexamethasone implant) is a small implant placed inside the eye that slowly releases a steroid medication over several months. Steroid implants can improve vision in close to one-third of people with BRVO (ASRS). However, steroids carry risks including increased eye pressure and cataract formation, so the retina specialist will weigh the benefits and risks carefully.
A retina specialist may recommend focal laser treatment for certain cases of BRVO. During this procedure, a laser creates tiny burns around the macula to help seal leaking blood vessels and reduce fluid buildup. Laser treatment is less commonly used as a first-line approach now that anti-VEGF injections are available, but it remains an option in specific situations.
If BRVO leads to ischemia and the growth of abnormal new blood vessels (neovascularization), scatter laser photocoagulation may be necessary. This treatment applies laser burns to the peripheral retina to reduce the demand for oxygen and shrink the abnormal vessels. Research has shown that scatter photocoagulation reduces neovascularization-related complications from 60 percent to 30 percent (ASRS).
What to Expect
Intravitreal injections are performed in the retina specialist's office. The eye is numbed with anesthetic drops, and the skin around the eye is cleaned with an antiseptic solution. A very fine needle is then used to inject the medication into the vitreous cavity. The procedure takes only a few minutes. Most people feel pressure or mild discomfort during and shortly after the injection.
After an injection, you may notice temporary blurred vision, mild redness, or a gritty sensation. These effects typically resolve within a day or two. The retina specialist will schedule follow-up appointments, usually every four to eight weeks initially, to check your retina with OCT and assess whether additional treatment is needed. Over time, the interval between visits and injections may be adjusted.
The visual outcome after BRVO varies from person to person. Some individuals recover a significant portion of their lost vision with treatment, while others may experience lasting changes. Early diagnosis and consistent treatment offer the best chance of preserving and improving vision. In clinical trials, patients who received anti-VEGF injections during the first year achieved considerable improvements in best-corrected visual acuity, and those with BRVO tended to retain these gains during the second year of follow-up (ASRS).
Living With Branch Retinal Vein Occlusion
Because BRVO is closely linked to systemic health problems, managing those conditions is an important part of your overall care. Work with your primary care doctor to keep blood pressure within a healthy range. If you have diabetes, maintaining good blood sugar control can help protect the blood vessels in your eyes. Addressing high cholesterol and maintaining a healthy weight are also beneficial steps.
Between appointments, pay attention to any changes in your vision. An Amsler grid, a simple chart with a grid pattern, can help you detect new distortion or blank spots. Your retina specialist may provide one and instruct you on daily use. If you notice any sudden changes, contact your retina specialist promptly.
Living with vision changes can be stressful. It is normal to feel frustrated or anxious about the diagnosis and the need for ongoing treatment. Support from family, friends, or a counselor can be helpful. Low vision aids, including magnifying devices and improved lighting, may make daily tasks like reading and cooking easier if vision remains affected despite treatment.
When to See a Retina Specialist
If you experience sudden blurry vision, new floaters, or a shadow across part of your visual field, see a retina specialist as soon as possible. These symptoms may indicate a new or worsening vein occlusion, macular edema, or the development of complications like neovascularization.
People with high blood pressure, diabetes, cardiovascular disease, or a history of retinal vein occlusion in one eye should have regular dilated eye exams. A retina specialist or general ophthalmologist can monitor the health of your retinal blood vessels and detect problems before they cause significant vision loss. Early detection remains one of the most effective ways to protect your eyesight.
Questions and Answers
Yes. Having BRVO in one eye increases the risk of developing a retinal vein occlusion in either the same eye or the other eye in the future. The underlying conditions that cause BRVO, such as high blood pressure and atherosclerosis, affect blood vessels throughout both eyes. Controlling these systemic risk factors is the most effective way to reduce the chance of a recurrence.
The number of injections varies for each person. Some patients need monthly injections for the first several months, followed by a gradual extension of the treatment interval. Others may require injections for a year or longer. Your retina specialist will use OCT imaging at each visit to assess macular swelling and determine the best schedule. The goal is to use the fewest injections needed to keep the macula dry and vision stable.
Vision recovery depends on several factors, including how much of the retina was affected, how quickly treatment began, and whether the macula sustained lasting damage. Many patients experience meaningful improvement in vision with anti-VEGF treatment, especially when therapy starts early. However, some degree of permanent vision change is possible, particularly if the blockage caused significant ischemia or nerve cell damage before treatment was initiated.
While there is no guaranteed way to prevent BRVO, managing the conditions that contribute to blood vessel damage can significantly lower your risk. Keeping blood pressure under control, managing diabetes and cholesterol levels, maintaining a healthy weight, exercising regularly, and avoiding smoking are all steps that support healthy retinal blood vessels. Regular eye exams allow for early detection if a problem does develop.